Logo image of LYRA

LYRA THERAPEUTICS INC (LYRA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LYRA - US55234L2043 - Common Stock

4.19 USD
+0.18 (+4.49%)
Last: 12/3/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LYRA. LYRA was compared to 192 industry peers in the Pharmaceuticals industry. LYRA may be in some trouble as it scores bad on both profitability and health. LYRA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LYRA has reported negative net income.
LYRA had a negative operating cash flow in the past year.
In the past 5 years LYRA always reported negative net income.
LYRA had a negative operating cash flow in each of the past 5 years.
LYRA Yearly Net Income VS EBIT VS OCF VS FCFLYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -75.38%, LYRA is doing worse than 71.35% of the companies in the same industry.
Industry RankSector Rank
ROA -75.38%
ROE N/A
ROIC N/A
ROA(3y)-78.35%
ROA(5y)-68.36%
ROE(3y)-314.8%
ROE(5y)-220.22%
ROIC(3y)N/A
ROIC(5y)N/A
LYRA Yearly ROA, ROE, ROICLYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LYRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYRA Yearly Profit, Operating, Gross MarginsLYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

LYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
LYRA has more shares outstanding than it did 1 year ago.
LYRA has more shares outstanding than it did 5 years ago.
LYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LYRA Yearly Shares OutstandingLYRA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
LYRA Yearly Total Debt VS Total AssetsLYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

LYRA has an Altman-Z score of -15.64. This is a bad value and indicates that LYRA is not financially healthy and even has some risk of bankruptcy.
LYRA's Altman-Z score of -15.64 is on the low side compared to the rest of the industry. LYRA is outperformed by 80.21% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.64
ROIC/WACCN/A
WACC9.06%
LYRA Yearly LT Debt VS Equity VS FCFLYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 2.43 indicates that LYRA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.43, LYRA is in line with its industry, outperforming 43.75% of the companies in the same industry.
A Quick Ratio of 2.43 indicates that LYRA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.43, LYRA perfoms like the industry average, outperforming 48.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.43
LYRA Yearly Current Assets VS Current LiabilitesLYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

LYRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.28%, which is quite impressive.
Looking at the last year, LYRA shows a very negative growth in Revenue. The Revenue has decreased by -59.21% in the last year.
LYRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 74.24% yearly.
EPS 1Y (TTM)69.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.44%
Revenue 1Y (TTM)-59.21%
Revenue growth 3Y74.24%
Revenue growth 5YN/A
Sales Q2Q%-87.18%

3.2 Future

Based on estimates for the next years, LYRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.65% on average per year.
Based on estimates for the next years, LYRA will show a very strong growth in Revenue. The Revenue will grow by 111.38% on average per year.
EPS Next Y72.46%
EPS Next 2Y36.5%
EPS Next 3Y23.95%
EPS Next 5Y14.65%
Revenue Next Year-50.15%
Revenue Next 2Y1.41%
Revenue Next 3Y95.96%
Revenue Next 5Y111.38%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LYRA Yearly Revenue VS EstimatesLYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
LYRA Yearly EPS VS EstimatesLYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600 -800 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LYRA. In the last year negative earnings were reported.
Also next year LYRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYRA Price Earnings VS Forward Price EarningsLYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYRA Per share dataLYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as LYRA's earnings are expected to grow with 23.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.5%
EPS Next 3Y23.95%

More info and screens

0

5. Dividend

5.1 Amount

LYRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LYRA THERAPEUTICS INC

NASDAQ:LYRA (12/3/2025, 8:00:01 PM)

4.19

+0.18 (+4.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-11 2026-03-11/amc
Inst Owners22.65%
Inst Owner Change-11.19%
Ins Owners0.02%
Ins Owner Change-0.09%
Market Cap7.42M
Revenue(TTM)600.00K
Net Income(TTM)-32.95M
Analysts48.89
Price Target23.46 (459.9%)
Short Float %2.78%
Short Ratio0.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.6%
Min EPS beat(2)10.27%
Max EPS beat(2)36.94%
EPS beat(4)3
Avg EPS beat(4)7.6%
Min EPS beat(4)-30.72%
Max EPS beat(4)36.94%
EPS beat(8)5
Avg EPS beat(8)-8.45%
EPS beat(12)8
Avg EPS beat(12)-2.76%
EPS beat(16)10
Avg EPS beat(16)-1.48%
Revenue beat(2)1
Avg Revenue beat(2)-41.33%
Min Revenue beat(2)-87.43%
Max Revenue beat(2)4.77%
Revenue beat(4)2
Avg Revenue beat(4)-18.5%
Min Revenue beat(4)-87.43%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)-10.71%
Revenue beat(12)7
Avg Revenue beat(12)20.41%
Revenue beat(16)8
Avg Revenue beat(16)12.56%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-112.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)13.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.89
EYN/A
EPS(NY)-9.79
Fwd EYN/A
FCF(TTM)-19.27
FCFYN/A
OCF(TTM)-19.29
OCFYN/A
SpS0.34
BVpS-2.45
TBVpS-2.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -75.38%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.35%
ROA(5y)-68.36%
ROE(3y)-314.8%
ROE(5y)-220.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.45%
Cap/Sales 6.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.43
Altman-Z -15.64
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)295.99%
Cap/Depr(5y)601.39%
Cap/Sales(3y)77.13%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.44%
EPS Next Y72.46%
EPS Next 2Y36.5%
EPS Next 3Y23.95%
EPS Next 5Y14.65%
Revenue 1Y (TTM)-59.21%
Revenue growth 3Y74.24%
Revenue growth 5YN/A
Sales Q2Q%-87.18%
Revenue Next Year-50.15%
Revenue Next 2Y1.41%
Revenue Next 3Y95.96%
Revenue Next 5Y111.38%
EBIT growth 1Y51.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.48%
OCF growth 3YN/A
OCF growth 5YN/A

LYRA THERAPEUTICS INC / LYRA FAQ

What is the fundamental rating for LYRA stock?

ChartMill assigns a fundamental rating of 2 / 10 to LYRA.


What is the valuation status for LYRA stock?

ChartMill assigns a valuation rating of 1 / 10 to LYRA THERAPEUTICS INC (LYRA). This can be considered as Overvalued.


How profitable is LYRA THERAPEUTICS INC (LYRA) stock?

LYRA THERAPEUTICS INC (LYRA) has a profitability rating of 0 / 10.


Can you provide the financial health for LYRA stock?

The financial health rating of LYRA THERAPEUTICS INC (LYRA) is 3 / 10.


What is the earnings growth outlook for LYRA THERAPEUTICS INC?

The Earnings per Share (EPS) of LYRA THERAPEUTICS INC (LYRA) is expected to grow by 72.46% in the next year.